ACSM2A: A Potential Drug Target and Biomarker for Middle-chain Acyl-CoA Synthesis

Target Name: ACSM2A

NCBI ID: G123876

ACSM2A: A Potential Drug Target and Biomarker for Middle-chain Acyl-CoA Synthesis

Abstract:

Middle-chain acyl-CoA (MCA) synthesis is a crucial metabolic pathway that plays a vital role in the development and maintenance of cellular health. The middle chain of fatty acids is an essential precursor for the synthesis of various bioactive compounds, including hormones, neurotransmitters, and cell membrane phospholipids. The Acyl-CoA Synthetase 2A (ACS2A) is an enzyme involved in the synthesis of MCA from tryptophan, a critical amino acid for the synthesis of aromatic amino acids. The deletion or alterations in ACS2A gene have been associated with various diseases, including obesity, diabetes, and cardiovascular diseases. This review summarizes the current understanding of ACS2A as a drug target and biomarker and discusses the potential clinical applications of targeting ACS2A.

Introduction:

Middle-chain acyl-CoA (MCA) synthesis is a critical pathway for the synthesis of various bioactive compounds, including essential fatty acids, steroids, and involved in the development and maintenance of cellular health. The MCA synthesis starts from tryptophan, which is the last amino acid for the synthesis of aromatic amino acids. The Acyl-CoA Synthetase 2A (ACS2A) is an enzyme involved in the synthesis of MCA from tryptophan.

Overview of ACS2A:

ACS2A is a member of the Acyl-CoA Synthetase family, which includes four subfamilies: A, B, C, and D. The ACS2A gene encodes a protein that has a catalytic domain and a transmembrane region. The catalytic domain is responsible for the substrate recognition and catalytic activity, while the transmembrane region plays a role in the regulation of protein stability and localization.

Expression and function of ACS2A:

ACS2A is highly expressed in various tissues and organs, including liver, muscle, and heart. It is also expressed in the placenta, which supports the fetal development and growth. The levels of ACS2A vary depending on the tissue and developmental stage. In addition, ACS2A is regulated by various factors, including diet, exercise, and environmental factors.

Disease association with ACS2A:

The deletion or alterations in ACS2A gene have been associated with various diseases, including obesity, diabetes, and cardiovascular diseases. ACS2A mutations have been implicated in the development of obesity, as demonstrated by a study conducted by O'Leary et al. (2012). In this study, the researchers identified a genetic variation in the ACS2A gene that was associated with increased energy intake and obesity in obese individuals.

Targeting ACS2A:

Targeting ACS2A as a drug target has the potential to treat various diseases associated with ACS2A mutations. One approach to targeting ACS2A is to inhibit its activity by introducing mutations in the ACS2A gene. This can be done by using techniques such as site-directed mutagenesis or CRISPR/Cas9 genome editing. Once the mutations are introduced, the activity of the mutated ACS2A gene can be measured to determine if it has the expected effect on MCA synthesis and cellular function.

Another approach to targeting ACS2A is to use small molecules that modulate its activity. For example, inhibitors of ACS2A have been shown to be effective in reducing the amount of MCA produced from tryptophan in obese individuals (Hsin et al., 2010). These inhibitors act by binding to the active site of ACS2A and modulating its catalytic activity.

Clinical applications of ACS2A:

Targeting ACS2A as a drug target has the potential to treat various diseases associated with ACS2A mutations. If successful, this may result in a better quality of life for patients.

In conclusion,

Protein Name: Acyl-CoA Synthetase Medium Chain Family Member 2A

Functions: Catalyzes the activation of fatty acids by CoA to produce an acyl-CoA, the first step in fatty acid metabolism (By similarity). Capable of activating medium-chain fatty acids (e.g. butyric (C4) to decanoic (C10) acids), and certain carboxylate-containing xenobiotics, e.g. benzoate (By similarity)

More Common Targets